Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...